Clinical & Experimental Metastasis最新文献_第7页

Molecular characterization of the histopathological growth patterns of colorectal cancer liver metastases by RNA sequencing of targeted samples at the tumor-liver interface. 通过肿瘤-肝脏界面靶向样本的RNA测序，研究结直肠癌肝转移组织病理生长模式的分子特征。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-12-12 DOI: 10.1007/s10585-024-10319-w

Emily Latacz, Sanne M L Verheul, Yasmine Sillis, Pieter-Jan van Dam, Michail Doukas, Dirk J Grunhagen, Hanna Nyström, Piet Dirix, Luc Dirix, Steven Van Laere, Cornelis Verhoef, Peter Vermeulen

{"title":"Molecular characterization of the histopathological growth patterns of colorectal cancer liver metastases by RNA sequencing of targeted samples at the tumor-liver interface.","authors":"Emily Latacz, Sanne M L Verheul, Yasmine Sillis, Pieter-Jan van Dam, Michail Doukas, Dirk J Grunhagen, Hanna Nyström, Piet Dirix, Luc Dirix, Steven Van Laere, Cornelis Verhoef, Peter Vermeulen","doi":"10.1007/s10585-024-10319-w","DOIUrl":"10.1007/s10585-024-10319-w","url":null,"abstract":"The behaviour of metastases in patients with liver-metastatic colorectal cancer (CRC) is still not adequately considered during treatment planning. However, studies in large cohorts have shown that the disease course in these patients depends on the histopathological growth pattern (HGP) of the liver metastases, with the desmoplastic (or encapsulated) pattern responsible for a favourable outcome and the replacement pattern for an unfavourable course. To increase our knowledge of cancer biology in general as well as to design clinical trials that take into account the diverse behaviour of liver metastases, it is necessary to know the cellular and molecular determinants of these growth patterns. For that purpose, we compared the transcriptome of tumour tissue (prospective cohort; n = 57) sampled very precisely at the transition of metastasis and adjacent liver, between the desmoplastic and replacement HGP. In addition, the mutational profiles for 46 genes related to CRC were extracted from the RNA sequencing reads. First, we show that the genetic constitution of a liver metastasis from colorectal cancer does not determine its HGP. Second, we show clear differences between HGPs regarding the expression of genes belonging to the Molecular Signatures Database hallmark gene sets. Biological themes of the replacement HGP reflect cancer cell proliferation and glucose metabolism, while the desmoplastic HGP is characterized by inflammation and immune response, and angiogenesis. This study supports the view that HGPs are a reflection of the biology of CRC liver metastases and suggests the HGPs are driven epigenetically rather than by specific gene mutations.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 1","pages":"1"},"PeriodicalIF":4.2,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting PADI2 as a potential therapeutic strategy against metastasis in oral cancer via suppressing EMT-mediated migration and invasion and CCL3/5-induced angiogenesis. 通过抑制 EMT 介导的迁移和侵袭以及 CCL3/5 诱导的血管生成，以 PADI2 为靶点作为抗口腔癌转移的潜在治疗策略。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-12-01 Epub Date: 2024-08-31 DOI: 10.1007/s10585-024-10310-5

Shih-Kai Hung, Chih-Chia Yu, Hon-Yi Lin, Wen-Yen Chiou, Moon-Sing Lee, Ru-Inn Lin, Ming-Chi Lu

{"title":"Targeting PADI2 as a potential therapeutic strategy against metastasis in oral cancer via suppressing EMT-mediated migration and invasion and CCL3/5-induced angiogenesis.","authors":"Shih-Kai Hung, Chih-Chia Yu, Hon-Yi Lin, Wen-Yen Chiou, Moon-Sing Lee, Ru-Inn Lin, Ming-Chi Lu","doi":"10.1007/s10585-024-10310-5","DOIUrl":"10.1007/s10585-024-10310-5","url":null,"abstract":"Oral squamous cell carcinoma (OSCC) is a prevalent and aggressive malignancy, with metastasis being the leading cause of death in patients. Unfortunately, therapeutic options for metastatic OSCC remain limited. Peptidylarginine deiminases (PADI) are implicated in various tumorigenesis and metastasis processes across multiple cancers. However, the role of PADI2, a type of PADI, in OSCC is not well understood. This study aimed to explore the impact of PADI2 on epithelial-mesenchymal transition (EMT), angiogenesis, and OSCC metastasis. The effect of PADI2 on EMT was evaluated using cell lines by Western blot analysis with shRNA targeting PADI2. In addition, the selective PADI2 inhibitor AFM32a was used to assess the effect of PADI2 on cancer metastasis and angiogenesis in animal models. Our findings indicated that PADI2 expression correlated with EMT changes, and PADI2 knockdown reversed these changes, reducing cell proliferation, cell migration, and invasion. PADI2 inhibition also diminished tube formation in HUVECs and decreased secretion of angiogenesis-related chemokines CCL3, CCL5 and CCL20. In a mouse model, AFM32a markedly reduced lung metastasis and production of CCL3 and CCL5. Our in vitro and in vivo studies suggested inhibiting PADI2 could prevent OSCC metastasis by impeding EMT and angiogenesis via AKT/mTOR signaling pathway. These results highlight PADI2 as a potential therapeutic target for combating OSCC metastasis.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"925-935"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model. PD-L1和血管内皮生长因子双重阻断增强血行转移模型中脑转移的抗肿瘤效果

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-12-01 Epub Date: 2024-09-05 DOI: 10.1007/s10585-024-10309-y

Chinami Masuda, Shinichi Onishi, Keigo Yorozu, Mitsue Kurasawa, Mamiko Morinaga, Daiko Wakita, Masamichi Sugimoto

{"title":"PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model.","authors":"Chinami Masuda, Shinichi Onishi, Keigo Yorozu, Mitsue Kurasawa, Mamiko Morinaga, Daiko Wakita, Masamichi Sugimoto","doi":"10.1007/s10585-024-10309-y","DOIUrl":"10.1007/s10585-024-10309-y","url":null,"abstract":"Immunotherapy improves survival outcomes in cancer patients, but there is still an unmet clinical need in the treatment of brain metastases. Here, we used a mouse model to investigate the antitumor effect of programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) dual blockade on metastatic brain tumors and evaluated immune responses during treatment. After establishing hematogenous brain metastasis by transplanting murine bladder carcinoma MBT2 cells stably expressing secNLuc reporter via the internal carotid artery of C3H/HeNCrl mice, we observed the formation of metastases not only in the brain parenchyma but also in the ventricles. The observed pathological areas showed that metastases in the ventricle were histologically larger than that in the brain parenchyma. Regarding the total tumor burden in the whole brain as revealed by Nluc activities, the combination of anti-PD-L1 antibody and anti-VEGF antibody showed a stronger anti-tumor effect than each single agent. Anti-PD-L1 antibody alone enhanced CD8+ T cell priming in regional lymph nodes, increased the proportion of activated CD8+ T cells in whole brain, and increased the density of CD8+ cells in the brain parenchyma. Furthermore, anti-VEGF antibody alone decreased microvessel density (MVD) in ventricular metastases, and the combination treatment increased intratumoral CD8+ cell density in the brain parenchyma and ventricular metastases. These results suggest that PD-L1 blockade enhanced cancer immunity not only in brain metastases lesions but also in the regional lymph nodes of the metastases, and that the addition of VEGF blockade increased the antitumor effect by increasing the infiltration of activated CD8+ T cell and decreasing MVD.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"909-924"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell blebbing novel therapeutic possibilities to counter metastasis. 细胞凋亡是对抗转移的新疗法。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-12-01 Epub Date: 2024-09-02 DOI: 10.1007/s10585-024-10308-z

Weiyi Jia, Marcus Czabanka, Thomas Broggini

{"title":"Cell blebbing novel therapeutic possibilities to counter metastasis.","authors":"Weiyi Jia, Marcus Czabanka, Thomas Broggini","doi":"10.1007/s10585-024-10308-z","DOIUrl":"10.1007/s10585-024-10308-z","url":null,"abstract":"Cells constantly reshape there plasma membrane and cytoskeleton during physiological and pathological processes (Hagmann et al. in J Cell Biochem 73:488-499, 1999). Cell blebbing, the formation of bulges or protrusions on the cell membrane, is related to mechanical stress, changes in intracellular pressure, chemical signals, or genetic anomalies. These membrane bulges interfere with the force balance of actin filaments, microtubules, and intermediate filaments, the basic components of the cytoskeleton (Charras in J Microsc 231:466-478, 2008). In the past, these blebs with circular structures were considered apoptotic markers (Blaser et al. in Dev Cell 11:613-627, 2006). Cell blebbing activates phagocytes and promotes the rapid removal of intrinsic compartments. However, recent studies have revealed that blebbing is associated with dynamic cell reorganization and alters the movement of cells in-vivo and in-vitro (Charras and Paluch in Nat Rev Mol Cell Biol 9:730-736, 2008). During tumor progression, blebbing promotes invasion of cancer cells into blood, and lymphatic vessels, facilitating tumor progression and metastasis (Weems et al. in Nature 615:517-525, 2023). Blebbing is a dominant feature of tumor cells generally absent in normal cells. Restricting tumor blebbing reduces anoikis resistance (survival in suspension) (Weems et al. in Nature 615:517-525, 2023). Hence, therapeutic intervention with targeting blebbing could be highly selective for proliferating pro-metastatic tumor cells, providing a novel therapeutic pathway for tumor metastasis with minimal side effects. Here, we review the association between cell blebbing and tumor cells, to uncover new research directions and strategies for metastatic cancer therapy. Finaly, we aim to identify the druggable targets of metastatic cancer in relation to cell blebbing.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"817-828"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lymph nodes in oral squamous cell carcinoma: a comprehensive anatomical perspective. 口腔鳞状细胞癌的淋巴结：全面解剖学视角。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-12-01 Epub Date: 2024-10-08 DOI: 10.1007/s10585-024-10317-y

Guang-Rui Wang, Nian-Nian Zhong, Lei-Ming Cao, Xuan-Hao Liu, Zi-Zhan Li, Yao Xiao, Kan Zhou, Yi-Fu Yu, Bing Liu, Lin-Lin Bu

{"title":"Lymph nodes in oral squamous cell carcinoma: a comprehensive anatomical perspective.","authors":"Guang-Rui Wang, Nian-Nian Zhong, Lei-Ming Cao, Xuan-Hao Liu, Zi-Zhan Li, Yao Xiao, Kan Zhou, Yi-Fu Yu, Bing Liu, Lin-Lin Bu","doi":"10.1007/s10585-024-10317-y","DOIUrl":"10.1007/s10585-024-10317-y","url":null,"abstract":"Oral squamous cell carcinoma (OSCC) often exhibits a propensity for metastasis to lymph nodes (LNs), significantly influencing prognosis. Neck dissection (ND) is an important part in the treatment of OSCC. Variations in the preference for and pathways of lymph node metastasis (LNM) in different regions of the oral cavity have been observed. Currently, there is a lack of sufficient emphasis on the anatomical perspectives of LNM and ND. This review elucidates the lymphatic system of the maxillofacial regions from an anatomical standpoint, details the distribution of the sentinel LNs across different subsites, and summarizes the various classifications of the cervical LNs. Additionally, we elaborate on the methods used to study the lymphatic system, particularly imaging techniques. Furthermore, we investigate the pathways of cervical LNM and evaluate the efficacy of ND from an anatomical viewpoint. The overall objective of this review is to provide essential anatomical knowledge for managing LNs in OSCC, in the hope of providing patients with effective treatment modalities to enhance their quality of life.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"877-890"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disrupting CENP-N mediated SEPT9 methylation as a strategy to inhibit aerobic glycolysis and liver metastasis in colorectal cancer. 将干扰 CENP-N 介导的 SEPT9 甲基化作为抑制结直肠癌有氧糖酵解和肝转移的一种策略。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-12-01 Epub Date: 2024-10-19 DOI: 10.1007/s10585-024-10316-z

Junge Bai, Zhexue Wang, Ming Yang, Jun Xiang, Zheng Liu

{"title":"Disrupting CENP-N mediated SEPT9 methylation as a strategy to inhibit aerobic glycolysis and liver metastasis in colorectal cancer.","authors":"Junge Bai, Zhexue Wang, Ming Yang, Jun Xiang, Zheng Liu","doi":"10.1007/s10585-024-10316-z","DOIUrl":"10.1007/s10585-024-10316-z","url":null,"abstract":"Colorectal cancer (CRC) is a prevalent malignancy with a high mortality rate, primarily due to liver metastasis. This study explores the role of centromere protein N (CENP-N) in mediating the methylation of septin 9 (SEPT9) and its subsequent effects on aerobic glycolysis and liver metastasis in CRC. We employed in vitro and in vivo experiments, including single-cell RNA sequencing, methylation-specific PCR (MSP), ChIP assays, and various functional assays to assess the impact of CENP-N and SEPT9 on CRC cell proliferation, migration, invasion, and metabolic reprogramming. Our data reveal that CENP-N directly interacts with SEPT9, enhancing its methylation at specific lysine residues. This modification significantly upregulates key glycolytic enzymes, thereby promoting aerobic glycolysis, CRC cell proliferation, and migration. In vivo studies further demonstrate that the CENP-N/SEPT9 axis facilitates liver metastasis of CRC, as confirmed by fluorescence imaging and histological analysis. This study identifies a novel pathway where CENP-N-mediated methylation of SEPT9 drives metabolic reprogramming and metastasis in CRC. These findings suggest potential therapeutic targets for inhibiting CRC progression and liver metastasis, offering new insights into CRC pathogenesis.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"971-988"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of PARPis combined with an ICIs for advanced or metastatic triple-negative breast cancer: a single-arm meta-analysis. PARPis 联合 ICIs 治疗晚期或转移性三阴性乳腺癌的有效性和安全性：单臂荟萃分析。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-12-01 Epub Date: 2024-09-04 DOI: 10.1007/s10585-024-10307-0

Qiao Zheng, Tiecheng Zhou, Weijun Ding

{"title":"Efficacy and safety of PARPis combined with an ICIs for advanced or metastatic triple-negative breast cancer: a single-arm meta-analysis.","authors":"Qiao Zheng, Tiecheng Zhou, Weijun Ding","doi":"10.1007/s10585-024-10307-0","DOIUrl":"10.1007/s10585-024-10307-0","url":null,"abstract":"Although the intervention for triple-negative breast cancer (TNBC) patients has improved and survival time has increased, the combination of immune checkpoint inhibitors(ICIs) and PARP inhibitors (Poly ADP-Ribose Polymerase inhibitors, PARPis) is still controversial. Previous studies revealed that the combined use of ICIs and PARPis led to increased antitumor activity. However, most of these combined regimens are nonrandomized controlled trials with small sample sizes. The purpose of this meta-analysis was to evaluate the efficacy and safety of ICIs combined with PARPis in patients with advanced or metastatic TNBC. The PubMed, Embase, Cochrane Library and Web of Science databases were systematically searched. The results including the objective remission rate (ORR), disease control rate (DCR), progression-free survival (PFS) and adverse events (AEs), were subjected to further analysis. Four studies involving 110 subjects were included in this meta-analysis. The combined ORR and DCR were 23.6% and 53.6%, respectively; while the ORR and DCR of BRCAmut patients were 38.1% and 71.4%, respectively. The median PFS of the patients was 4.29 months. As for safety, the most common AEs were nausea (49.0%), anemia (44.3%) and fatigue (40.6%). Most of them were grade 1 or 2, and the incidence of adverse events ≥ III was obviously low. Except for anemia, the incidence of AEs ≥ III was < 10%. This meta-analysis revealed that the combination of ICIs and PARPis has good efficacy and safety for advanced or metastatic TNBC patients.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"843-850"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical resection versus stereotactic radiosurgery for the treatment of brain metastases in the motor cortex; a meta-analysis and systematic review. 治疗运动皮层脑转移瘤的手术切除与立体定向放射外科手术；荟萃分析与系统综述。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-12-01 Epub Date: 2024-09-20 DOI: 10.1007/s10585-024-10311-4

Dong-Won Shin, Gi-Taek Yee

{"title":"Surgical resection versus stereotactic radiosurgery for the treatment of brain metastases in the motor cortex; a meta-analysis and systematic review.","authors":"Dong-Won Shin, Gi-Taek Yee","doi":"10.1007/s10585-024-10311-4","DOIUrl":"10.1007/s10585-024-10311-4","url":null,"abstract":"Brain metastasis in the motor cortex is a challenging condition to treat. Surgical resection or stereotactic radiosurgery (SRS)/hypofractionated stereotactic radiotherapy (hypoSRT) are valuable options up to now. Due to its unique location and potential for neurologic deficits, neither treatment is entirely satisfactory. There is still a lack of data on the treatment result of motor cortex metastasis. This study provides a comprehensive review and meta-analysis comparing surgery and SRS/hypoSRT for treating brain metastasis in the motor cortex. Core databases, including PubMed, Embase, and the Cochrane Library, were systematically searched for brain metastasis in the motor cortex, demonstrating the clinical outcomes of both surgery and SRS/hypoSRT. Motor power outcome and treatment-associated complication rates were thoroughly evaluated. Twenty-five articles were listed for full-text review. Among them, 13 articles were eligible for inclusion criteria: retrospective cohort studies comparing surgery and SRS/hypoSRT. There are 323 patients in the surgery group and 220 in the SRS/hypoSRT group. The motor outcome is better in surgery group, but without statistical significance (0.49 vs 0.37, p = 0.3937) and treatment-related complication is lower in surgery group with statistical significance (0.09 vs 0.26, p = 0.0218). Treatment modality should be tailored by the patient's performance status, history of radiation, presence of ongoing chemotherapy, or extracranial progression status.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"851-862"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives. 乳腺癌少进展转移部位的局部治疗：疗效、毒性和未来展望。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-12-01 Epub Date: 2024-09-23 DOI: 10.1007/s10585-024-10312-3

Filippo Merloni, Michela Palleschi, Caterina Gianni, Marianna Sirico, Riccardo Serra, Chiara Casadei, Samanta Sarti, Lorenzo Cecconetto, Giandomenico Di Menna, Marita Mariotti, Roberta Maltoni, Daniela Montanari, Antonino Romeo, Ugo De Giorgi

{"title":"Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives.","authors":"Filippo Merloni, Michela Palleschi, Caterina Gianni, Marianna Sirico, Riccardo Serra, Chiara Casadei, Samanta Sarti, Lorenzo Cecconetto, Giandomenico Di Menna, Marita Mariotti, Roberta Maltoni, Daniela Montanari, Antonino Romeo, Ugo De Giorgi","doi":"10.1007/s10585-024-10312-3","DOIUrl":"10.1007/s10585-024-10312-3","url":null,"abstract":"Metastatic breast cancer (MBC) is still an incurable disease, which eventually develops resistance mechanisms against systemic therapies. While most patients experience widespread disease progression during systemic treatment (ST), in some cases, progression may occur at a limited number of metastatic sites. Evidence from other malignancies suggests that local treatment with stereotactic ablative radiotherapy (SABR) of oligoprogressive disease (OPD) may allow effective disease control without the need to modify ST. Available evidence regarding local treatment of oligoprogressive breast cancer is limited, mostly consisting of retrospective studies. The only randomized data come from the randomized CURB trial, which enrolled patients with oligoprogressive disease, including both small cell lung cancer and breast cancer patients, and did not show a survival benefit from local treatment in the latter group. However, local treatment of oligoprogressive MBC is still considered in clinical practice, especially to delay the switch to more toxic STs. This review aims to identify patients who may benefit from this approach based on the current available knowledge, focusing also on the potential risks associated with the combination of radiotherapy (RT) and ST, as well as on possible future scenarios.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"863-875"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11606987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer. 局部中/高危和转移性前列腺癌循环肿瘤细胞的多标记分析

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-12-01 Epub Date: 2024-09-21 DOI: 10.1007/s10585-024-10313-2

Eva Welsch, Lilli Bonstingl, Barbara Holzer, Eva Schuster, Esther Weiß, Alexandru-Teodor Zaharie, Michael Krainer, Michael B Fischer, Amin El-Heliebi, Robert Zeillinger, Eva Obermayr

{"title":"Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer.","authors":"Eva Welsch, Lilli Bonstingl, Barbara Holzer, Eva Schuster, Esther Weiß, Alexandru-Teodor Zaharie, Michael Krainer, Michael B Fischer, Amin El-Heliebi, Robert Zeillinger, Eva Obermayr","doi":"10.1007/s10585-024-10313-2","DOIUrl":"10.1007/s10585-024-10313-2","url":null,"abstract":"Circulating tumor cells (CTCs) are an established prognostic marker in metastatic prostate cancer (PrC) but have received little attention in localized high-risk disease. Peripheral blood was obtained from patients with early intermediate and high-risk PrC (n = 15) at baseline, after radiotherapy, and during follow-up, as well as from metastatic PrC patients (n = 23). CTCs were enriched using the microfluidic Parsortix® technology. CTC-related marker were quantified with qPCR and RNA in-situ hybridization (ISH). Positivity and associations to clinical parameters were assessed using McNemar test, Fisher Exact test or log-rank test. The overall positivity was high in both cohorts (87.0% metastatic vs. 66.7% early at baseline). A high concordance of qPCR and RNA ISH was achieved. In metastatic PrC, PSA and PSMA were prognostic for shorter overall survival. In early PrC patients, an increase of positive transcripts per blood sample was observed from before to after radiation therapy, while a decrease of positive markers was observed during follow-up. CTC analysis using the investigated qPCR marker panel serves as tool for achieving high detection rates of PrC patient samples even in localized disease. RNA ISH offers the advantage of confirming these markers at the single cell level. Employing the clinically relevant marker PSMA, our CTC approach can be used for diagnostic purposes to screen patients profiting from PSMA-directed PET-CT or PSMA-targeted therapy.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"937-945"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0